# CitroTech Inc.: financial statements, quarterly

CITR · NYSE · CIK 894556 · [Materials](/sectors/materials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/citr.md) · [Financials](/companies/citr/financials.md) · [Filings](/companies/citr/filings.md) · [Insiders](/companies/citr/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/citr/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.2](/filings/0001640334-24-001748.md) | [0.3 d](/filings/0001640334-25-000558.md) | [0.4](/filings/0001640334-25-000913.md) | [0.2](/filings/0001640334-25-001490.md) | [0.1](/filings/0001640334-25-002055.md) | [0.1 d](/filings/0001683168-26-002356.md) | [1.0](/filings/0001683168-26-003943.md) | [0.7](/filings/0001683168-26-006123.md) | [0.3](/filings/0001640334-25-002055.md) | [0.4 d](/filings/0001683168-26-002356.md) | [0.3](/filings/0001683168-26-003943.md) | [0.3](/filings/0001683168-26-006123.md) |
| Cost of revenue | $m | [0.0](/filings/0001640334-23-002165.md) | [0.1 d](/filings/0001640334-25-000558.md) | [0.1](/filings/0001640334-25-000913.md) | [0.1](/filings/0001640334-25-001490.md) | [0.1](/filings/0001640334-25-002055.md) | [0.3 d](/filings/0001683168-26-002356.md) | [0.6](/filings/0001683168-26-003943.md) | [0.4](/filings/0001683168-26-006123.md) | [0.6](/filings/0001640334-25-002055.md) | [0.3 d](/filings/0001683168-26-002356.md) | [0.2](/filings/0001683168-26-003943.md) | [0.3](/filings/0001683168-26-006123.md) |
| Gross profit | $m | [0.1](/filings/0001640334-23-002165.md) | [0.2 d](/filings/0001640334-24-000667.md) | [0.3](/filings/0001640334-24-000811.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001683168-26-003943.md) | [0.0](/filings/0001683168-26-006123.md) | not reported | not reported | [0.1](/filings/0001683168-26-003943.md) | [0.2](/filings/0001683168-26-006123.md) |
| Operating income | $m | [(9.1)](/filings/0001640334-24-001748.md) | [(0.2) d](/filings/0001640334-25-000558.md) | [(2.6)](/filings/0001640334-25-000913.md) | [(0.9)](/filings/0001640334-25-001490.md) | [(0.6)](/filings/0001640334-25-002055.md) | [(1.2) d](/filings/0001683168-26-002356.md) | [(3.5)](/filings/0001683168-26-003943.md) | [(3.0)](/filings/0001683168-26-006123.md) | [(4.2)](/filings/0001640334-25-002055.md) | [(5.8) d](/filings/0001683168-26-002356.md) | [(4.4)](/filings/0001683168-26-003943.md) | [(3.5)](/filings/0001683168-26-006123.md) |
| Interest expense | $m | [0.0](/filings/0001640334-24-001748.md) | [0.0 d](/filings/0001640334-24-001174.md) | [0.0](/filings/0001640334-25-000913.md) | [0.0](/filings/0001640334-25-001490.md) | [0.1](/filings/0001640334-25-002055.md) | [0.2 d](/filings/0001683168-26-002356.md) | [0.4](/filings/0001683168-26-003943.md) | [0.6](/filings/0001683168-26-006123.md) | [0.4](/filings/0001640334-25-002055.md) | [0.2 d](/filings/0001683168-26-002356.md) | [0.2](/filings/0001683168-26-003943.md) | [0.0](/filings/0001683168-26-006123.md) |
| Income tax | $m | [0.0](/filings/0001640334-24-001748.md) | [0.0 d](/filings/0001640334-25-000558.md) | [0.0](/filings/0001640334-25-000913.md) | [0.0](/filings/0001640334-25-001490.md) | [0.0](/filings/0001640334-25-002055.md) | [0.0 d](/filings/0001683168-26-002356.md) | [0.0](/filings/0001683168-26-003943.md) | [0.0](/filings/0001683168-26-006123.md) | [0.0](/filings/0001640334-25-002055.md) | [0.0 d](/filings/0001683168-26-002356.md) | [0.0](/filings/0001683168-26-003943.md) | [0.0](/filings/0001683168-26-006123.md) |
| Net income | $m | [(9.1)](/filings/0001640334-24-001748.md) | [(0.2) d](/filings/0001640334-25-000558.md) | [(3.5)](/filings/0001640334-25-002055.md) | [(0.9)](/filings/0001640334-25-002055.md) | [(0.7)](/filings/0001640334-25-002055.md) | [(1.8) d](/filings/0001683168-26-002356.md) | [(10.9)](/filings/0001683168-26-006123.md) | [(11.9)](/filings/0001683168-26-006123.md) | [(7.9)](/filings/0001640334-25-002055.md) | [(6.1) d](/filings/0001683168-26-002356.md) | [(6.2)](/filings/0001683168-26-006123.md) | [(3.9)](/filings/0001683168-26-006123.md) |
| Diluted EPS | $ per share | [(0.09)](/filings/0001640334-24-001748.md) | not reported | [(0.04)](/filings/0001640334-25-000913.md) | [(0.02)](/filings/0001640334-25-001490.md) | [(0.11)](/filings/0001640334-25-002055.md) | not reported | [(1.37)](/filings/0001683168-26-003943.md) | [(1.14)](/filings/0001683168-26-006123.md) | [(0.59)](/filings/0001640334-25-002055.md) | not reported | [(0.33)](/filings/0001683168-26-003943.md) | [(0.18)](/filings/0001683168-26-006123.md) |
| Basic EPS | $ per share | not reported | not reported | [(0.04)](/filings/0001640334-24-001211.md) | [(0.02)](/filings/0001640334-24-001286.md) | not reported | not reported | [(1.37)](/filings/0001683168-26-003943.md) | [(1.14)](/filings/0001683168-26-006123.md) | not reported | not reported | [(0.33)](/filings/0001683168-26-003943.md) | [(0.18)](/filings/0001683168-26-006123.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [0.5](/filings/0001640334-25-000558.md) | [0.4](/filings/0001640334-24-001211.md) | [0.5](/filings/0001640334-24-001286.md) | [0.3](/filings/0001640334-24-001748.md) | [0.8](/filings/0001683168-26-002356.md) | [3.7](/filings/0001640334-25-000913.md) | [2.3](/filings/0001640334-25-001490.md) | [6.2](/filings/0001640334-25-002055.md) | [6.3](/filings/0001683168-26-006123.md) | [4.3](/filings/0001683168-26-003943.md) | [2.5](/filings/0001683168-26-006123.md) |
| Current assets | $m | [0.9](/filings/0001640334-23-002165.md) | [1.2](/filings/0001640334-25-000558.md) | [1.3](/filings/0001640334-24-001211.md) | [1.4](/filings/0001640334-24-001286.md) | [1.1](/filings/0001640334-24-001748.md) | [1.6](/filings/0001683168-26-002356.md) | [5.0](/filings/0001640334-25-000913.md) | [3.8](/filings/0001640334-25-001490.md) | [7.3](/filings/0001640334-25-002055.md) | [7.4](/filings/0001683168-26-006123.md) | [5.6](/filings/0001683168-26-003943.md) | [3.7](/filings/0001683168-26-006123.md) |
| Total assets | $m | [5.3](/filings/0001640334-23-002165.md) | [5.3](/filings/0001640334-25-000558.md) | [5.3](/filings/0001640334-24-001211.md) | [5.4](/filings/0001640334-24-001286.md) | [4.9](/filings/0001640334-24-001748.md) | [5.5](/filings/0001683168-26-002356.md) | [9.1](/filings/0001640334-25-000913.md) | [8.7](/filings/0001640334-25-001490.md) | [12.3](/filings/0001640334-25-002055.md) | [14.2](/filings/0001683168-26-006123.md) | [12.2](/filings/0001683168-26-003943.md) | [10.0](/filings/0001683168-26-006123.md) |
| Current liabilities | $m | [1.7](/filings/0001640334-23-002165.md) | [1.6](/filings/0001640334-25-000558.md) | [1.5](/filings/0001640334-24-001211.md) | [2.1](/filings/0001640334-24-001286.md) | [2.1](/filings/0001640334-24-001748.md) | [2.2](/filings/0001683168-26-002356.md) | [5.0](/filings/0001640334-25-000913.md) | [5.8](/filings/0001640334-25-001490.md) | [3.0](/filings/0001640334-25-002055.md) | [2.2](/filings/0001683168-26-006123.md) | [2.9](/filings/0001683168-26-003943.md) | [0.4](/filings/0001683168-26-006123.md) |
| Total liabilities | $m | [1.8](/filings/0001640334-23-002165.md) | [1.7](/filings/0001640334-25-000558.md) | [1.5](/filings/0001640334-24-001211.md) | [2.1](/filings/0001640334-24-001286.md) | [2.1](/filings/0001640334-24-001748.md) | [2.2](/filings/0001683168-26-002356.md) | [5.0](/filings/0001640334-25-000913.md) | [6.5](/filings/0001640334-25-001490.md) | [3.8](/filings/0001640334-25-002055.md) | [2.9](/filings/0001683168-26-006123.md) | [3.6](/filings/0001683168-26-003943.md) | [1.0](/filings/0001683168-26-006123.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001640334-25-002055.md) | not reported | not reported | [0.1](/filings/0001640334-25-002055.md) | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | [0.0](/filings/0001640334-25-000558.md) | not reported | not reported | not reported | [0.1](/filings/0001640334-25-002055.md) | [0.0](/filings/0001640334-25-000913.md) | [0.0](/filings/0001640334-25-001490.md) | [0.0](/filings/0001640334-25-002055.md) | not reported | not reported | not reported |
| Shareholders' equity | $m | [3.3](/filings/0001640334-24-001748.md) | [3.6](/filings/0001683168-26-002356.md) | [3.8](/filings/0001640334-25-002055.md) | [3.2](/filings/0001640334-25-002055.md) | [2.8](/filings/0001640334-25-002055.md) | [3.3](/filings/0001683168-26-006123.md) | [4.1](/filings/0001683168-26-006123.md) | [2.2](/filings/0001683168-26-006123.md) | [8.5](/filings/0001640334-25-002055.md) | [11.3](/filings/0001683168-26-006123.md) | [8.7](/filings/0001683168-26-006123.md) | [9.0](/filings/0001683168-26-006123.md) |

- Cash and equivalents: us-gaap:Cash, us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(396) d](/filings/0001640334-24-001748.md) | [(392) d](/filings/0001640334-25-000558.md) | [(344)](/filings/0001640334-25-000913.md) | [(425) d](/filings/0001640334-25-001490.md) | [(551) d](/filings/0001640334-25-002055.md) | [(618) d](/filings/0001683168-26-002356.md) | [(714)](/filings/0001683168-26-003943.md) | [(1,212) d](/filings/0001683168-26-006123.md) | [(1,461) d](/filings/0001640334-25-002055.md) | [(2,482) d](/filings/0001683168-26-002356.md) | [(2,059)](/filings/0001683168-26-003943.md) | [(1,783) d](/filings/0001683168-26-006123.md) |
| Capital expenditure | $k | [2.2 d](/filings/0001640334-24-001748.md) | [1.8 d](/filings/0001640334-25-000558.md) | [0.0](/filings/0001640334-25-000913.md) | [0.0 d](/filings/0001640334-25-001490.md) | [0.0 d](/filings/0001640334-25-002055.md) | [0.0 d](/filings/0001683168-26-002356.md) | [27.0](/filings/0001683168-26-003943.md) | [141 d](/filings/0001683168-26-006123.md) | [53.9 d](/filings/0001640334-25-002055.md) | [(27.7) d](/filings/0001683168-26-002356.md) | [10.7](/filings/0001683168-26-003943.md) | [0.0 d](/filings/0001683168-26-006123.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [93.9](/filings/0001640334-22-002372.md) | [113](/filings/0001640334-23-000866.md) | [113](/filings/0001640334-23-001591.md) | [97.5](/filings/0001640334-24-001748.md) | [92.2](/filings/0001640334-25-000913.md) | [36.4](/filings/0001640334-25-001490.md) | [6.1](/filings/0001640334-25-002055.md) | [8.0](/filings/0001683168-26-003943.md) | [10.5](/filings/0001683168-26-006123.md) | [13.5](/filings/0001640334-25-002055.md) | [18.8](/filings/0001683168-26-003943.md) | [21.8](/filings/0001683168-26-006123.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 22,553,474 at 2026-08-07, from the cover of the [10-Q/A filed 2026-08-10](/filings/0001683168-26-006123.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:27 ET. No prices; not investment advice.